НАЛ ФАРМАСЬЮТИКАЛ ГРУП ЛИМИТЕД (CN);МО, Джозеф, И. (US)
发明人:
МО, Джозеф, И. (US),ЧУ, Чун Квонг (CN)
申请号：
RU2019106796
公开号：
RU2019106796A
申请日:
2017.06.27
申请国别(地区):
RU
年份:
2020
代理人:
摘要：
The invention is related to fusion proteins of human somatostatin (e.g., SST-14 or SST-28) and human serum albumin, comprising a region at least 85% homologous to human somatostatin and a region at least 85% homologous to human serum albumin or a region with a partial amino acid sequence of human serum albumin, wherein linker peptide sequences may be present between somatostatin and somatostatin moieties or somatostatin and albumin moieties. Also disclosed are constructs wherein the somatostatin moiety contains multiple tandem repeats of a somatostatin sequence. In selected embodiments, the orientation of the somatostatin and albumin moieties can be varied, and such sequences may impact the binding and efficacy of the disclosed fusion proteins. Also disclosed are methods of making and using the aforementioned constructs. The somatostatin-albumin fusion protein demonstrated enhanced stability when incubated in rat plasma in vitro and prolonged plasma half-life in vivo compared with free somatostatin.
